The emergence of dual-action receptor agonists in the approach of type 2 diabetes and obesity has sparked considerable interest, particularly regarding retatrutide and tirzepatide. While both medications target both https://joshftmn368391.gynoblog.com/37727391/retatrutide-vs-tirzepatide-a-comparative-analysis